Geron Corporation (GERN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Foster City, CA, アメリカ. 現CEOは Harout Semerjian.
GERN を有する IPO日 1996-07-31, 229 名の正社員, に上場 NASDAQ Global Select, 時価総額 $1.08B.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
